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Abstract
Background: Some isolates of the Liverpool cystic fibrosis epidemic strain of Pseudomonas
aeruginosa exhibit an unusual virulence-related phenotype, characterized by over-production of
quorum sensing-regulated exoproducts such as pyocyanin and LasA protease. Our aim was to
determine the prevalence of this unusual phenotype amongst isolates of the epidemic strain, and
to study other intraclonal phenotypic and genotypic variations.
Results: The unusual phenotype was detected in at least one epidemic strain isolate from the
majority of cystic fibrosis patients tested, and can be retained for up to seven years during chronic
infection. Multiple sequential isolates of the epidemic strain taken from six patients over a period
of up to nine years exhibited a wide range of phenotypes, including different antimicrobial
susceptibilities. Our data suggest that each sputum sample contains a mixture of phenotypes and
genotypes within the epidemic strain population, including within colony morphotypes. Many
isolates exhibit premature (during early rather than late exponential growth) and over-production
of pyocyanin, which has a number of toxic effects directly relevant to cystic fibrosis.
Conclusion: The widespread occurrence of this unusual phenotype suggests that it may play an
important role in the success of the epidemic strain.
Background
With a carrier rate of 1 in 25 and an incidence of 1 in
2,500 live births, cystic fibrosis (CF) is the most common
life-threatening, recessively inherited disease amongst
Caucasians. During chronic pulmonary infection, CF
patients suffer decline in lung function associated with
periodic exacerbations triggered by bacterial products.
The most widespread CF pathogen is Pseudomonas aerugi-
nosa, which causes infections that, once established, are
impossible to eradicate.
The blue, redox-active phenazine pyocyanin is secreted by
P. aeruginosa under the control of its cell-density-depend-
ent quorum sensing (QS) system [1]. Pyocyanin and its
precursor phenazine-1-carboxylic acid (PCA) have a
number of toxic effects relevant to CF [2,3]. Pyocyanin
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vitro [4,5], and alter expression of immunomodulatory
proteins by human airway epithelial cells [6]. For exam-
ple, increases in IL-8 and intercellular adhesion molecule-
1 (ICAM-1) expression by oxidant-dependent mecha-
nisms have been demonstrated in vitro and in vivo [6,7].
It has also been shown that pyocyanin production by P.
aeruginosa induces neutrophil apoptosis and impairs neu-
trophil-mediated host defenses in vitro [8] and in vivo [9].
Furthermore, Kong et al. [10] have demonstrated that
physiologically relevant concentrations of pyocyanin
inactivate the airway vacuolar ATPase, resulting in
reduced expression of CF transmembrane conductance
regulator (CFTR) in cultured lung and nasal epithelial
cells.
In 1996 Cheng et al. [11] used molecular typing to dem-
onstrate the spread of a drug-resistant strain of P. aerugi-
nosa [named the Liverpool Epidemic Strain (LES)]
amongst patients in a children's CF centre in Liverpool,
UK. Analysis of post-2000 patient samples identified the
LES in 79% of 80 P. aeruginosa-colonised CF patients in
the Liverpool adult CF centre, confirming the spread and
longevity of LES infections [12]. Furthermore, a survey of
31 CF centres in England and Wales, involving the analy-
sis of more than 1200 isolates of P. aeruginosa, identified
the LES as the most common clone, being present in 48%
of CF centres and accounting for 11% of the isolates [13].
In addition to its transmissibility, the LES appears to be
more aggressive than other P. aeruginosa strains. It has
been shown to replace previously established strains of P.
aeruginosa (superinfection) [14], and it has infected both
non-CF parents of a CF patient, causing significant mor-
bidity [15]. In addition, there is evidence for greater mor-
bidity amongst CF patients colonised with the LES
compared to those carrying non-epidemic strains of P. aer-
uginosa [16].
Recently, we demonstrated that some LES isolates express
an unusual phenotype characterized by the early and
over-expression of QS-regulated virulence genes, includ-
ing those encoding the secretion of pyocyanin, LasA and
elastase [17]. The unusual phenotype was called hypervir-
ulence because of increased virulence in a Drosophila infec-
tion model [17]. Here we refer to it as the over-production
(of pyocyanin; OP) phenotype. We reported previously
that this phenotype was detected in isolates from both
non-CF parents and the CF patient of the unusual infec-
tion episode [15] but was lacking from an isolate
(LES400) associated with a chronic infection [17].
In this paper, we determine the prevalence of LES isolates
exhibiting the OP phenotype amongst adult CF patients
in Liverpool, and report a wider analysis of LES isolates
with respect to phenotypic and genotypic variations.
Results
Efficacy of a simple Luria broth test for pyocyanin 
production
In order to test the efficacy of a simple screening proce-
dure for pyocyanin production by strains of P. aeruginosa,
the amount of pyocyanin in culture supernatants after
overnight growth was quantified by measuring the A695
value for 10 environmental strains, 10 strains associated
with bacterial keratitis, 29 non-LES CF and 48 LES isolates
(Figure 1). Absorbance values for the supernatants of cul-
tures of LES isolates were significantly higher than those
for non-LES CF isolates (p = 0.004) or non-CF isolates (p
= 0.015). When the known LES lasR mutants were
removed from this analysis, the significance levels were
increased further (p < 0.001 and p = 0.003 respectively).
Prevalence of the OP phenotype
A total of 34 non-LES (each isolated from a different CF
patient) and 55 LES isolates (isolated from 16 different CF
patients and confirmed as LES by PFGE and/or PS21 PCR
assay) of P. aeruginosa were screened for over-production
of pigment by using the simple broth test. Overall, 51% of
the LES isolates produced an increased blue/green colora-
tion (above that of strain PA01) but 49% had normal or
lower than normal pigment production. All of the non-
LES isolates fell into the latter category. We selected all
potential LES pyocyanin over-producers, and a selection
of the other LES isolates, for further study using the full
pyocyanin production assay. A wide range of pyocyanin
production was observed (Figure 2). We grouped these
activities as either (i) OP (pyocyanin A695 > 0.1 at cell den-
sity A600 = 1.2); (ii) Intermediate (pyocyanin A695 > 0.1 at
cell density A600 = 1.7); (iii) Normal (pyocyanin detecta-
ble, similar to strain PA01) or Negative (no detectable
pyocyanin activity). Using these criteria the LES isolates
analysed could be separated according to pyocyanin pro-
duction into 49% OP (n = 20), 17% Intermediate (n = 7),
34% Normal or Negative (n = 14). We did not sub-divide
the latter two categories because of the difficulty in assign-
ing those strains that did not reach equivalent cell densi-
ties to strain PA01. There was considerable variation in the
amount of time taken for cultures of the different isolates
to reach equal cell densities. Of the 20 CF patients from
whom 1–6 isolates were subjected to study, 13 carried at
least one OP isolate, and a further four carried at least one
isolate of "intermediate" phenotype. For three CF
patients, the isolates tested all had either a normal or a
negative pyocyanin phenotype. We also screened six non-
LES CF isolates using the full pyocyanin production assay.
All fell into the categories Normal or Negative (data not
shown).Page 2 of 10
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multiple isolates from individual patients
We identified six CF patients (patient A-F) from whom we
had archived, multiple and sequential isolates of the LES
(1995–2004). For each patient there was a minimum of
four different LES isolates and three different sampling
dates. There was considerable variation in the colony mor-
phologies of the panel isolates. For each of these isolates
both the pyocyanin activity and the LasA activity were
assayed (Table 1). In addition, we determined the antimi-
crobial susceptibilities and, for the majority of isolates,
assigned them to a LES pulsotype using PFGE (Table 1).
There were widespread variations in both pulsotype and
antimicrobial susceptibility data between isolates taken
from the same patients.
We tested the panel of isolates for the common mutant
phenotypes auxotrophy, lack of swimming motility and
hypermutability. Six of the isolates (B55, B67, B41, 109,
49194, B48), from four different patients, exhibited the
hypermutable phenotype. Only three isolates were unable
to grow on glucose M9 media. These were all isolated
from patient B (B46, 49194, B48) and two of the three
were hypermutable isolates. All of the panel isolates were
non-motile.
Variations in pyocyanin production against cell density
for LES isolates taken from patients A-F are shown in Fig-
ures 3 and 4. There was no general consensus in the results
obtained. There was some evidence for temporal loss of
the OP phenotype in patients A, B and E. The earliest iso-
late from patient A (from 1995) was of OP phenotype.
However, the other isolate with the OP phenotype was
isolated in 2000. Isolates from patient A included four
identical non-OP lasR mutants, one of which was isolated
in 1998. For patient B, early isolates were OP-positive
whereas later ones were negative. For patient E, only one
of two earliest isolates was OP-positive whereas all other
isolates were OP-negative. For both patient B and patient
E, two isolates from the same isolation time had different
phenotypes with respect to pyocyanin production and
LasA activity. This phenomenon could also be observed in
patients C, D and F. However, isolates from both 1996
and 2003 from patient C had the OP phenotype. A similar
longevity can be demonstrated with the data from patient
B. In patient D, none of the isolates had a clear OP pheno-
type, whereas in patient F, the earliest isolate was non-OP
whereas the most recent was OP-positive.
Correlation between the OP phenotype and antimicrobial 
susceptibilities
Table 2 summarises the distribution of the OP-positive,
OP-negative and other LES isolates according to resistance
or susceptibility to five antimicrobial agents. According to
the φ2 test for statistical significance, in a comparison
between isolates that were OP-positive and other isolates,
there was a correlation between the presence of the OP
phenotype and resistance to either ceftazidime (p =
0.006), aztreonam (p = 0.044) or meropenem (p = 0.037)
(Table 2).
lasR mutations are associated with loss of pyocyanin 
production
We analysed 17 of the pyocyanin-negative isolates for
mutations in the lasR gene. Of these, lasR mutations were
identified in 11 isolates (Table 3). As controls we also
sequenced the lasR gene from five pyocyanin producers
and confirmed that none were mutated (Table 3). Thus
lasR mutations were significantly more frequent amongst
pyocyanin-negative isolates (φ2 test, p = 0.011). All of the
lasR mutations that we have found in LES isolates to date
are summarized in Table 3.
Discussion
We have demonstrated that an unusual phenotype, char-
acterised by early- and over-production of QS-regulated
virulence factors such as the exoproducts pyocyanin and
LasA protease, is widespread amongst CF isolates of the
LES. In a simple broth test for pyocyanin production,
whereby cultures were incubated overnight in 5 ml cul-
tures, the levels of pyocyanin were lower than those meas-
ured during exponential growth in 50 ml cultures. It is
likely that this was either due to some breakdown of pyo-
Pyocyanin production in culture supernatants after overnight gr wth i Luria brothFigure 1
Pyocyanin production in culture supernatants after 
overnight growth in Luria broth. Mean absorbance val-
ues are shown for isolates of P. aeruginosa falling into the fol-
lowing categories: (a) water isolates (n = 10); (b) keratitis 
isolates (n = 10); (c) non-LES CF isolates (n = 29); (d) all LES 
isolates (n = 48); (e) LES isolates omitting known lasR 
mutants (n = 38); (f) LES known lasR mutants (n = 10); (g) 
strain PA01.
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50 ml cultures in 250 ml flasks. Hence, although the sim-
ple broth test is a useful screening tool, the full assay gives
a better indication of actual levels of pyocyanin produc-
tion.
A recent study sought to assess the genetic adaptation of P.
aeruginosa strains during CF infections by whole genome
analysis of sequential isolates [18]. The authors concluded
that virulence factors required for initiation of acute infec-
tions are often selected against during chronic infection.
Amongst those mutations leading to the loss of virulence-
associated phenotypes, lasR mutations were the most
common [18]. Indeed, the observation that lasR mutants
are common amongst clinical and environmental isolates
of P. aeruginosa has led to the suggestion that the QS sys-
tem may have a negative impact on the organism's fitness
[19]. If this is the case, then the unusual OP phenotype of
the LES might be expected to amplify any negative impact.
However, we found evidence that the OP phenotype can
persist amongst isolates within a patient for periods in
excess of five years (patients A, B and C) and up to seven
years (patients B and C). To our knowledge there are no
other reported instances of natural isolates of P. aeruginosa
that exhibit the OP phenotype. Given that the OP pheno-
type places a considerable metabolic burden on the bacte-
ria, the retention of such a high-maintenance phenotype
within LES populations suggests that there may be some
selective advantage. The fact that the OP phenotype is
retained increases the possibility that it may play a role in
the transmissibility of the strain. Interestingly, we also
found that the same lasR mutant can persist within a
patient for up to six years (patient A). We did not find
complete correlation between pyocyanin over-production
and high levels of LasA activity. This suggests that second-
ary mutations not affecting the whole QS regulon also
lead to diverse phenotypes in LES populations.
CF isolates are often non-motile or auxotrophic. In one
study, 33% of CF patients had a mean percentage auxo-
troph count of more than 50% total cfu/ml [20]. Oliver et
al. [21] reported an overall prevalence for the hypermuta-
ble phenotype amongst CF isolates of P. aeruginosa as
20%. In our study, we found that LES isolates exhibiting
the hypermutable phenotype comprised 18% of the iso-
lates from the six CF patients. It has been suggested that
the hypermutator phenotype plays an important role in
the development of multiple-antimicrobial resistance in
P. aeruginosa strains causing chronic lung infections [22].
However, we found little evidence that hypermutable iso-
lates were less susceptible to antimicrobials than other
non-hypermutable isolates from the same patient (Table
1).
Variations in colony morphology are also commonplace.
Normal laboratory practice when dealing with sputum
samples is to select a limited number of the most numer-
ous colony morphotypes for storage, antimicrobial sus-
ceptibity profiling and occasionally strain typing.
Morphology has been linked to increased virulence in the
case of small colony variants (SCV) [23]. However, it has
also been demonstrated that identical colony morpho-
types sharing the same genotype can vary in activities such
as antimicrobial susceptibility [24]. In our study, isolates
obtained from an individual patient at the same sampling
time differed in morphology, but there are a number of
examples with sequential isolates where the same colony
morphotype and genotype exhibited variations in antimi-
crobial susceptibity and/or QS-regulated activities. If pul-
sotype variation is discounted there are further examples
suggesting that colony morphotype is an imperfect basis
for the selection of isolate variants (Table 1). It has already
Pyocyanin assays on LES isolatesFigure 2
Pyocyanin assays on LES isolates. Production of pyocy-
anin in culture supernatants during growth of LES isolates in 
L-broth is shown for all the LES isolates tested in this study. 
Each combination of colour and shape plotted represents a 
different LES isolate. The only non-LES isolate included is 
strain PA01 (blue squares, indicated by the arrow). LES iso-
lates could be sub-divided on the basis of pyocyanin assays 
into various groups: (i) OP (early- and over-production of 
pyocyanin) [circles]. (ii) Intermediate [diamonds]. (iii) Nor-
mal or negative [squares]
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isolates vary widely [12,17].
The LES was first identified in a CF unit where ceftazidime
monotherapy was being used as standard antipseudomo-
nal treatment for respiratory exacerbations [11]. The
authors suggested that the strategy of monotherapy had
contributed to the success of the ceftazidime-resistant LES.
Blázquez and colleagues [25] have not only suggested that
ceftazidime concentrations thought previously to be
lethal are not, but that ceftazidime treatment can increase
the frequency at which P. aeruginosa mutates. Thus, it is
entirely plausible that the strategy of ceftazidime therapy
may have contributed to the emergence of the OP pheno-
type exhibited by the LES.
Although first identified because of the spread of a mul-
tiresistant clone in a CF unit [11], it is clear that isolates of
the LES vary considerably in their antimicrobial suscepti-
bility profiles. We found an interesting correlation
between the OP phenotype and resistance to the β-
lactams ceftazidime, aztreonam and meropenem. It has
been demonstrated recently that pyocyanin can act as a
signalling molecule in P. aeruginosa strains PA01 and
PA14, upregulating in late exponential or stationary
phase, a limited number of genes from the QS network,
including the mexGHI-opmD genes involved in efflux,
redox processes and iron acquisition [26]. We have
reported previously that these genes are up-regulated in
late exponential phase in the OP-positive isolate LES431
when compared to either an OP-negative LES isolate or
strain PA01 [17]. Not only does this highlight another
possible consequence of the early and over-production of
pyocyanin in LES populations, but it suggests that pyocy-
anin itself may play a direct role in the observed link
between antimicrobial susceptibilities and the OP pheno-
type.
Our data clearly support the notion that bacterial popula-
tions in the sputum samples of CF patients are mixed with
respect to both genotype and phenotype, even when iso-
lates represent the same clone. We saw many minor vari-
Table 1: Phenotypes and genotypes of sequential LES isolates from six CF patients
Patient Year Isolate PFGE Pyocyanin (OP phenotype) LasA{SD} lasR mut. CAZ MER ATM TOB CIP Colony morphology
A 1995 B7 I-II + 24.2 {4.9} NO R R R D D SCV,NM,Ra,S
A 1998 B32 I-II - 98.4 {7.2} YES S R S D S SCV,NM,F,S
A 2000 B45 ID-II - 67.3 {1.9} nd R R R R S NM,F,S
A 2003 B25 I-II - 98.6 {0.6} YES S R S S S NM,Ra,S
A 2003 B70 IC-II - 82.7 {5.1} NO R R R S S M,Ra,S
A 2004 49111 ND - 98.7 {1.6} YES S R S S S NM,Ra,RW
A 2004 49074 ND - 97.0 {1.5} YES R R R S S NM,Ra,S
B 1996 B46 IH-IIE + 81.6 {2.2} NO R R R D D SCV,NM,F,S
B 1998 B38 I-II + 84.8 {2.9} NO R R R D S NM,Ra,S
B 2003 B60 IE-II + 20.6 {1.9} nd R R R D S NM,F,S
B 2003 B48 I-II - 93.2 {0.9} NO S R R S S M,Ra,S
B 2004 49194 ND - 93.6 {0.9} NO S S S S R NM,Ra,S
C 1996 B49 IC-II + 43.3 {4.4} nd R R S S S SCV,NM,F,S
C 1998 B40 I-II + 20.3 {2.3} nd S R S R S SCV,NM,F,S
C 1998 B41 I-II - 98.6 {1.3} YES S R S D S NM,Ra,S
C 1998 109 ND + 82.7 {1.1} nd S S S S S NM,F,S
C 2003 B64 I-II - 95.2 {1.8} NO S S S S D SCV,NM,F.S
C 2003 B65 I-II + 8.61 {7.8} nd S R S D S NM,Ra,S
C 2004 49137 ND INT 63.4 {3.4} nd S S S D R SCV,NM,F,S
D 1996 B28 IC-II - 41.3 {5.5} NO S R S S S SCV,NM,F,S
D 1998 B35 IC-II INT 96.6 {1.2} NO S S S D S SCV,NM,F,S
D 2002 B61 IC-II NOR 3.33 {4.4} nd R R S R D NM,Ra,S
D 2002 B62 I-IIG - 95.3 {5.4} YES S S S S S SCV,NM,F,S
D 2002 B63 I-II - 98.5 {1.9} YES S R S R S NM,Ra,S
E 1995 B4 IC-II - 95.2 {2.0} YES S S S R S NM,Ra,S
E 1995 B57 I-II + 26.8 {3.2} NO R R R S D NM,Ra,S
E 2000 B50 I-II - 96.4 {3.6} NO R R R S S M,Ra,S
E 2000 B51 I-II - 98.4 {2.6} YES S S S R S SCV,NM,Ra,S
E 2002 B67 ID-IIB - 98.4 {2.9} YES R R R S D NM,F,S
F 1996 B30 I-II - 98.5 {1.0} YES S S R R S SCV,NM,Ra,S
F 2000 B55 I-II NOR 34.8 {4.4} nd S S S S S M,Ra,S
F 2002 B68 IA-II NOR 88.5 {4.4} nd S S S S S NM,F,S
F 2002 B69 IB-IID + 31.6 {5.6} nd R R R R S NM,F,S
PFGE refers to pulsotypes obtained with SpeI and XbaI respectively; LasA activity indicates the percentage of the initial (time zero) A600 value remaining after 60 min; SD: 
standard deviation for four replicates; lasR mut. refers to whether the isolate is a confirmed lasR mutant or not by sequencing; ND: not determined; antimicrobial agent 
abbreviations are ceftazidime (CAZ), aztreonam (ATM), meropenem (MER), tobramycin (TOB) and ciprofloxacin (CIP); colony morphology was scored as mucoid (M), non-
mucoid (NM), flat (F) raised (Ra), smooth (S), rough/wrinkled (RW), small colony variant (SCV). For OP phenotype: + indicates OP-positive; - indicates OP-negative; INT 
indicates intermediate; NOR indicates normal.Page 5 of 10
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Pyocyanin production by sequential isolates from CF patients A-CFigure 3
Pyocyanin production by sequential isolates from CF patients A-C. Production of pyocyanin in culture supernatants 
during growth of LES isolates in L-broth is shown for isolates from three CF patients (patient A-F).  Chronological order of iso-
lation is indicated by colour from the earliest to the most recent in the following order : yellow (1995), red (1996), blue (1998), 
black (2000), green (2003) and orange (2004).  Different isolates from the same year are indicated by different shapes.
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Pyocyanin production by sequential isolates from CF patients D-FFigure 4
Pyocyanin production by sequential isolates from CF patients D-F. Production of pyocyanin in culture supernatants 
during growth of LES isolates in L-broth is shown for isolates from three CF patients (patient D-F).  Chronological order of 
isolation is indicated by colour from the earliest to the most recent in the following order : yellow (1995), red (1996), blue 
(1998), black (2000) and pink (2002).  Different isolates from the same year are indicated by different shapes.
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BMC Microbiology 2007, 7:45 http://www.biomedcentral.com/1471-2180/7/45ations in PFGE banding patterns between isolates of the
LES, even between isolates taken from the same sputum
sample. The LES seems to have an unstable genotype
[13,27], suggesting that individuals within LES popula-
tions undergo deletions, insertions and rearrangements.
As well as these quite large genetic events, there are often
point mutations leading to significant phenotypic
changes. A study analysing greater numbers of isolates
from each sputum sample may give a far better insight
into the diversity within populations of P. aeruginosa in CF
than the snapshot obtained when analysing relatively
small numbers.
Conclusion
Isolates of a CF epidemic strain of P. aeruginosa exhibit
considerable phenotypic and genotypic diversity. The OP
phenotype, characterized by de-regulation of the QS sys-
tem leading to increased production of exoproducts
including pyocyanin, is common amongst LES isolates
and can persist within CF patients for several years. The
presence and widespread nature of such an unusual phe-
notype amongst populations of a highly successful CF epi-
demic strain, suggests that the OP phenotype may play an
important role in the success of the LES.
Methods
Bacterial strains
The bacterial strains used in this study were mainly iso-
lates of P. aeruginosa from adults and children attending
CF centres in Liverpool between 1995 and 2004. 34 non-
LES isolates were obtained from 21 male and 13 female
adult CF patients. The 55 LES isolates were obtained from
10 male and six female CF patients and included isolates
from both adults and children over 14 years old. Of the
LES isolates, 33 were from patients colonised with the LES
for > 4 years whereas 22 were from patients colonised
Table 3: LES lasR mutants
LES 
isolate
lasR Mutation Comments/Reference
LESB41 deletion of CCGGGCTGGCTACG leading to divergence from position R66 onward isolated from patient C
LESB30 single point mutation leading to divergence from position S33 onward isolated from patient F
LESB32 single nucleotide insertion/frame-shift mutation leading to divergence from position L223 onward isolated from patient A
LESB25 same as LESB32 isolated from patient A
LES49111 same as LESB32 isolated from patient A
LES49074 same as LESB32 isolated from patient A
LESB63 same as LESB32 isolated from patient D
LESB62 single point mutation leading to single amino acid change H224 → R isolated from patient D
LESB4 same as LESB32 isolated from patient E
LESB51 same as LESB32 isolated from patient E
LESB67 deletion of AAGCGGAA leading to divergence from position A134 onward isolated from patient E
LES49220 single point mutation leading to single amino acid change G235 → D CF isolate, isolated in 2004
LES400 repetition of GGTGCTC leading to divergence from G123 onward [17]
LES430 deletion of GTGGATGCTC leading to divergence from position W152 onwards [17]
LESB44 insertion of GAAG leading to divergence from position I35 onwards [17]
Table 2: Comparison between antimicrobial susceptibility and OP phenotype of LES isolates
Antimicrobial agent % resistant LES isolates for different OP phenotypes
OP (n = 11) Negative (n = 17) N or I (n = 5)
CAZ R 73 24 20
ATM R 64 35 0
MER R 91 65 20
TOB R 27 24 20
TOB D 45 12 40
CIP R 0 6 20
CIP D 27 12 20
CAZ, ceftazidime; ATM, aztreonam; MER, meropenem; TOB, tobramycin; CIP, ciprofloxacin; R, resistant; D, intermediate antimicrobial 
susceptibility; N, normal; I, intermediate OP phenotypePage 8 of 10
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LES-positive cultures. Similar data was not available for
the non-LES isolates because strain-specific identification
is carried out routinely only for the LES.
Ten P. aeruginosa strains associated with bacterial keratitis
[28] and ten environmental water isolates [29] were used
to assess levels of pyocyanin production by non-CF iso-
lates. All strains were stored in glycerol-Luria broth at -
80°C and cultured on Luria agar at 37°C. Strain PA01
[30] was used as a control.
Phenotypic tests
Auxotrophy was tested by determining the ability to grow
on glucose M9 minimal media. Swimming motility was
assessed by inoculating bacteria on to the surface of 0.3%
(w/v) agar plates containing 1% (w/v) tryptone and 0.5%
(w/v) NaCl. The diameter of the swimming zone was
measured after incubation at 37°C for 24 h. Each isolate
was tested in triplicate. Hypermutability was assessed by
determining spontaneous mutation rates on Luria agar
containing rifampicin (300 μg/ml) following overnight
growth in Luria broth as described previously [21]. Col-
ony morphology was observed on MacConkey agar plates.
Typing by pulsed-field gel electrophoresis (PFGE) and PS21 
PCR assay
PFGE of SpeI- or XbaI-digested genomic DNA was carried
out using 1% (w/v) agarose gels. Isolates with identical
banding patterns were considered to be genetically indis-
tinguishable and isolates with banding patterns differing
by three or fewer bands to be clonal variants (pulsotypes)
of the same strain. The PS21 PCR assay for identification
of the LES has been described previously [31].
Assays for QS-regulated phenotypes
Pyocyanin and LasA protease assays were carried out on
culture supernatants during growth in Luria broth as
described previously [17]. The amount of pyocyanin in
culture supernatants was quantified by measuring the A695
value. For overnight cultures, it was important to shake
the culture vigorously before obtaining the supernatant.
This is to ensure that all of the pyocyanin present is in the
oxidized form [32]. LasA protease activity was measured
by determining the ability of P. aeruginosa culture super-
natants to lyse boiled Staphylococcus aureus cells leading to
a decrease in A600. Activity was expressed as the percentage
of the initial (time zero) A600 value remaining after 60
min.
We used a simple broth test to identify strains with
increased blue/green pigment production compared to
strain PA01. Following overnight growth in universals
containing 5 ml Luria broth, with shaking at 200 RPM,
cultures were scored as either (i) greater pigment produc-
tion than strain PA01 or (ii) similar or less pigment pro-
duction than strain PA01. For validation of the test,
pyocyanin production, as measured by A695 values in cul-
ture supernatants, was compared for various categories of
P. aeruginosa isolates. Statistical significance was tested by
using a one way ANOVA test (MINITAB 14.0, Minitab
Inc.). Full pyocyanin production assays were carried out
using 250 ml flasks containg 50 ml Luria broth.
Identification of lasR mutations
PCR amplification was carried out as described previously
[31]. Amplification of the las region was carried out using
the oligonucleotide primer sets lasRF (5'- GTGCCGAATC-
CATATTTG-3')/lasRR (5'-CCTTCCCTATATATCTGC-3')
and lasF1 (5'- GGGTATTCAGTTCGCATA -3')/lasR1 5'-
CCCAAATTAACGGCCATA-3') to amplify overlapping
regions which can be combined to cover the whole lasR
gene. PCR amplicons were purified using S-400 microspin
columns (Amersham-Pharmacia Biotech) and sequenced
by Lark Technologies Inc. using the same oligonucleotide
primers employed in the PCR amplification.
Antimicrobial susceptibility tests
Antimicrobial susceptibility was assessed by disk diffu-
sion tests according to BSAC guidelines [33] using disks
(Oxoid) containing ceftazidime (30 μg), meropenem (10
μg), aztreonam (30 μg), tobramycin (10 μg) and cipro-
floxacin (5 μg). Breakpoints for sensitive (S), intermediate
(D) and resistant (R) organisms were according to BSAC
guidelines.
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